S
Stephen R. D. Johnston
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 236
Citations - 10861
Stephen R. D. Johnston is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 51, co-authored 205 publications receiving 8905 citations. Previous affiliations of Stephen R. D. Johnston include American Society of Clinical Oncology & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Charlotte Fribbens,Ben O'Leary,Lucy Kilburn,Sarah Hrebien,Isaac Garcia-Murillas,Matthew Beaney,Massimo Cristofanilli,Fabrice Andre,Sherene Loi,Sibylle Loibl,John Jiang,Cynthia Huang Bartlett,Maria Koehler,Mitch Dowsett,Judith M Bliss,Stephen R. D. Johnston,Nicholas C. Turner +16 more
TL;DR: ESR1 mutation analysis in plasma after progression after prior AI therapy may help direct choice of further endocrine-based therapy, and improve progression-free survival after taking fulvestrant.
Journal ArticleDOI
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han Koh,EM Grischke,Pierfranco Conte,Yi Lu,Susana Barriga,Karla Hurt,Martin Frenzel,Stephen R. D. Johnston,Antonio Llombart-Cussac +18 more
TL;DR: The addition of abemaciclib to fulvestrant provided a clinically meaningful median OS benefit of 9.4 months for patients with HR-positive, ERBB2-negative advanced breast cancer that had progressed on endocrine therapy.
Journal ArticleDOI
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo,R. Bryan Rumble,Erin Macrae,Debra L. Barton,Hannah Klein Connolly,Maura N. Dickler,Lesley Fallowfield,Barbara Fowble,James N. Ingle,Mohammad Jahanzeb,Stephen R. D. Johnston,Larissa A. Korde,James Khatcheressian,Rita S. Mehta,Hyman B. Muss,Harold J. Burstein +15 more
TL;DR: This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC, and aromatase inhibitors (AIs) are the preferred first-line endocrine Therapy, with or without the cyclin-dependent kinase inhibitor palbociclib.
Journal ArticleDOI
Aromatase inhibitors for breast cancer: lessons from the laboratory
TL;DR: An alternative strategy of oestrogen deprivation in postmenopausal women with aromatase inhibitors is set to replace tamoxifen based on better efficacy and a delay in the emergence of endocrine resistance.
Journal ArticleDOI
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Stephen R. D. Johnston,Miguel Martin,Angelo Di Leo,Seock-Ah Im,Ahmad Awada,T. Forrester,Martin Frenzel,Molly C. Hardebeck,Joanne Cox,Susana Barriga,Masakazu Toi,Hiroji Iwata,Matthew P. Goetz +12 more
TL;DR: Abemaciclib nearly doubled the time women live without disease recurrence, from 15 months on placebo to 28 months on the drug, and the safety profile was consistent with previous reports.